Latest news with #JBChemicals
Business Upturn
12 hours ago
- Business
- Business Upturn
Top stocks in focus on June 25: JB Chemicals, Infosys, PTC Industries, HAL, IRCTC, and more
By Aman Shukla Published on June 25, 2025, 08:21 IST The Indian stock market is set for an eventful session on Wednesday, June 25, with several companies announcing fresh developments that could draw investor attention. Here's a look at key corporate news and updates that may influence stock movement: JB Chemicals received US FDA approval for its generic Amitriptyline Hydrochloride tablets, expanding its regulated market portfolio. Infosys announced a strategic tie-up with Zoetis, aimed at boosting IT and digital operations using AI and automation solutions. Aurobindo Pharma's subsidiary CuraTeQ Biologics received marketing approval in the UK for Dyrupeg, a biosimilar of pegylated filgrastim. Servotech Renewable won a ~16 MW rooftop solar project from Madhya Pradesh Urja Vikas Nigam Ltd, strengthening its clean energy pipeline. PTC Industries' subsidiary Aerolloy Technologies signed an MoU with Safran Aircraft Engines to develop a domestic manufacturing ecosystem for military aircraft engines. Bajel Projects secured a large substation order in India valued between Rs 1–2 billion. Glenmark Pharmaceuticals launched lung cancer drug Tevimbra in the Indian market. IndiGo reported a slight rise in market share for May, climbing to 64.6% from 64.1% the previous month. KFin Technologies reappointed Vishwanathan Mavila Nair as Chairman for a one-year term starting October 1, 2025. IRCTC is likely to be in focus as Indian Railways prepares for a nationwide fare hike across all passenger categories starting July 1. HAL confirmed that the Indian Air Force will receive at least six Tejas fighter jets by March 2026. Bondada Engineering landed a Rs 836 crore order for battery energy storage systems from Tamil Nadu Green Energy Corporation, to be executed over 12 years. Ashok Leyland announced plans to expand its commercial vehicle footprint by adding 50 new outlets in North India. Hindalco said its US-based subsidiary, Aditya Holdings LLC, will acquire AluChem Companies Inc., a specialty alumina producer, for $125 million. India Glycols reported record-high sales of its alcoholic beverage brand 'Bunty Bubbly' for FY24–25. Supreme Infrastructure secured a Rs 4.5 billion turnkey project in Mumbai, taking its total order book to Rs 17.25 billion. Rites received a letter of intent for a Rs 28.5 crore infrastructure project from Gujarat Urban Development Company. CWD Ltd announced an initial order worth Rs 8 crore from a leading digital services provider. Several companies reported key management changes, including India Gelatine, Kabra Extrusion, Rathi Steel, Vibhor Steel, and National Plastic, all involving resignations of company secretaries or senior officers. Enviro Infra received a GST department notice over tax dues totaling Rs 8.4 crore for the period FY19–FY24. Vodafone Idea clarified that it has not received any formal communication from the government regarding potential relief on its outstanding dues. CIE Automotive will invest Rs 2.6 crore to acquire up to 29% in AMP Energy C&I Thirty Two Private Ltd. Petronet LNG, Ador Welding, and Automobile Corporation of Goa announced record dates for their final dividends. India Cements, Mahindra & Mahindra, Bharat Bijlee, and HSCL reported credit rating updates and investment activities that may influence their respective valuations. Lloyd Metals completed the acquisition of a 26.82% stake in HR Godavari Private Limited for Rs 17.4 crore. Mastek said CFO Raghavendra Jha will step down on July 11, 2025. Kaynes Technology closed its Qualified Institutional Placement, issuing 28.73 lakh shares at Rs 5,569.50 per share. BLS E-Services announced it will acquire customer service points of SBI and HDFC Bank through its subsidiary under a deal worth around Rs 6.5 crore. Union Bank of India revoked the appointment of Pankaj Dwivedi as Executive Director with immediate effect. Dredging Corporation of India was removed from the Short-Term Additional Surveillance Measure (ASM) list. Several companies are trading ex-date today, including Elitecon International (stock split), Quest Capital, Aegis Logistics, and Automobile Corporation of Goa (dividends). Infibeam Avenues is scheduled to open its rights issue tomorrow, June 26. CG Power received a tax notice from the Income Tax Department proposing an additional liability of Rs 1,194.54 crore following a draft assessment order. Timex Group promoters are looking to offload a 15% stake in the India unit via an Offer for Sale at Rs 175 per share. Tata Motors may see global headwinds as Jaguar Land Rover faces potential exposure of up to £1.6 billion due to proposed US tariffs. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash HALInfosysIRCTCJB ChemicalsPTC IndustriesStock Market Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
16-05-2025
- Business
- Yahoo
J.B. Chemicals & Pharmaceuticals Ltd (BOM:506943) Q4 FY25 Earnings Call Highlights: Strong ...
Revenue: INR949 crores, a 10% year-on-year increase for Q4 FY25. Operating EBITDA: INR240 crores, a 15% increase, with a margin of 25.3%. Net Profit: INR146 crores, a 15% improvement. Gross Margin: 66.1%, marking a 90 basis points expansion. Domestic Business Revenue: INR519 crores, an 11% year-on-year growth. International Business Revenue: INR430 crores, a 9% year-on-year growth. Chronic Portfolio Growth: 16% year-on-year improvement in Q4 FY25. Ophthalmology Business Growth: 22% to INR56 crores in Q4 FY25. CDMO Revenue: INR129 crores, an 18% growth for the quarter. Operating Cash Flow: INR903 crores for FY25, with an 83% operating cash flow to EBITDA ratio. ROCE: 32% for FY25, up from 27% in FY24. Net Cash: INR689 crores as of March 31, 2025. Dividend: Total dividend of INR15.50 per share for FY25. Warning! GuruFocus has detected 4 Warning Signs with IVCGF. Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. J.B. Chemicals & Pharmaceuticals Ltd (BOM:506943) reported a 10% increase in revenue for Q4 FY25, reaching INR949 crores. Operating EBITDA expanded by 15% to INR240 crores, demonstrating strong efficiency and execution capabilities. The domestic business grew by 11% year-on-year, outperforming the industry growth rate of 7%. The company has successfully integrated five acquisitions, enhancing its market position. International operations saw a 9% growth, driven by a strong performance in the CDMO business, which grew by 18%. The international business growth was limited to 4% for the full year, with challenges in the South Africa and BGX segments. The API business has been declining over the past two years, with limited growth prospects. The company faces potential risks related to the Rantac product, although no ban has been implemented yet. The trade generics segment remains a negligible part of the business, with no significant focus on expansion. Sequential decline in the India business was noted, attributed to seasonal factors affecting the industry. Q: Can you provide the breakup of India business excluding ophthalmic in terms of price, volume, and new product launch for the year? A: Excluding ophthalmology, our domestic business growth was close to 12%, with volume growth at 6%. The remaining growth was due to price and new introductions. Compared to the market, which had sub-2% volume growth, our performance was strong. - Kunal Khanna, President - Operations Q: Can you highlight which segments in the chronic portfolio have outperformed for J.B. Chemicals? A: Our key chronic brands like Cilacar, Cilacar-T, Nicardia, and Razel have outperformed the market. For example, Cilacar plain grew at 19% versus the market's 16%, and Cilacar-T grew at 37% compared to the market's 25%. - Kunal Khanna, President - Operations Q: What is the current status of the Rantac brand given the expert panel's recommendation to suspend ranitidine? A: There is no ban on Rantac. It continues to be available due to its strong clinical efficacy and safety profile. The government has instructed manufacturers to closely monitor quality, which we have been doing. - Kunal Khanna, President - Operations Q: What is the strategy for the export formulation business, especially in Russia, South Africa, and other branded generic markets? A: Our international business is structured into four clusters, focusing on tenders and progressive portfolio filings. We expect new products to start commercializing by early FY27, leading to growth in these markets. - Nikhil Chopra, CEO and Whole-time Director Q: Can you provide guidance on the CDMO segment and its future prospects? A: The CDMO segment grew by 18% this quarter. We are working on new projects, including lozenges and throat sprays, which will be commercialized by the end of the year. We expect the quarterly run rate to increase from INR110 crores to INR150 crores. - Nikhil Chopra, CEO and Whole-time Director Q: What is the expected impact of the Ophthal portfolio on profitability after the perpetual license triggers in December 2026? A: The Ophthal portfolio's gross margin will align with our domestic business, significantly enhancing profitability. We expect the portfolio to reach an annualized run rate of INR230 crores by FY27. - Kunal Khanna, President - Operations Q: How do you see the international formulation sales evolving over the next couple of years? A: We expect the CDMO business to grow by 12% to 14%, with South Africa and Russia showing positive trends. The branded generics export business should see growth from FY27 onwards with new product launches. - Nikhil Chopra, CEO and Whole-time Director Q: What is the company's stance on trade generics, and will there be a focus on this segment? A: Trade generics is not a focus area for us. It contributes negligibly to our India business, and we do not plan to heavily invest in this segment. - Kunal Khanna, President - Operations For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
